One of the most current discussions these days is about the benefits of using the medicinal plant Cannabis sativa, generally known as marijuana or cannabis. Studies have been proving the effectiveness of cannabidiol as a therapeutic resource in psychic disorders, such as anxiety, schizophrenia and epilepsy. Latter, is a chronic disorder that occurs mainly in childhood and adolescence, characterized by excessive and abnormal activity of brain cells. The purpose of this paper is to evaluate the applicability of Cannabidiol against the symptoms of epilepsy, being a retrospective review from articles published in the period of 2014 to 2018. In 2001, studies demonstrated the efficacy of cannabidiol in the treatment of seizures in children. Unlike the adverse side effects of current antiepileptic drugs, such as dizziness and vomiting, the effects of cannabidiol are almost nonexistent, in both short and long term use. The mechanism of action of cannabidiol is given by activating Cannabidiol receptors (CB1 and CB2) that coupled to an inhibitory G protein acts on the receptors by inhibiting synaptic transmission by blocking voltage-dependent calcium-activated potassium channels. In this context, cannabidiol (CBD) exerts its anticonvulsive function through neuroprotective mechanisms or through neural excitation/inhibition balance. Thus, it is believed that the endocannabinoid system can inhibit episodes of seizures. Studies indicate that this active substance should be used with a vaporizer to reduce the harmful effects of smoke, as well as its use in oil, especially for children and adolescents. Therefore, research has shown that Cannabidiol has broad therapeutic potential in central nervous system disorders, but further studies should be performed, both for the confirmation of these pharmacological effects and for proper approval in the treatment of seizures.